AF Anticoagulation After ICH: Current Strategies
Oral Anticoagulants Show Net Clinical Benefit in Patients with Intracranial Hemorrhage, Meta-analysis Reveals
Table of Contents
A recent meta-analysis published in teh Journal of the American College of Cardiology suggests that oral anticoagulants (OACs) offer a net clinical benefit for patients who have experienced intracranial hemorrhage (ICH), primarily by significantly reducing the risk of ischemic stroke and systemic thromboembolism. however, the study also highlights a notable increase in the risk of recurrent ICH.
Key Findings on Oral Anticoagulant Use Post-ICH
The thorough meta-analysis, which included data from multiple trials, focused on the outcomes of patients with a history of ICH who were afterward treated with OACs. The average follow-up period for patients in the included studies ranged from a mean of 0.53 years to a median of 1.9 years.The primary endpoint assessed was net adverse clinical events (NACE), a composite measure that included ischemic stroke, systemic thromboembolism, nonfatal myocardial infarction, cardiovascular death, recurrent ICH, and extracranial major bleeding.
Oral Anticoagulant Breakdown and Efficacy
The study provided a detailed breakdown of the OACs used in the analyzed trials:
Apixaban: 65%
Edoxaban: 15%
Dabigatran: 14%
rivaroxaban: 4%
Warfarin: 1%
The findings indicated that the use of OACs was associated with a meaningful reduction in NACE, with a relative risk (RR) of 0.69 (95% CI, 0.52-0.93), representing a 31% decrease. More strikingly, OACs demonstrated a considerable 76% reduction in the risk of ischemic stroke or systemic thromboembolism (RR, 0.24; 95% CI, 0.09-0.61).This translates to a number needed to treat (NNT) of 12 for preventing NACE and an NNT of 8 for preventing ischemic stroke or systemic thromboembolism.
Increased Risk of Recurrent Intracranial Hemorrhage
Despite the significant benefits in preventing ischemic events,the meta-analysis also identified a concerning increase in the risk of recurrent ICH. Oral anticoagulants were associated with a more than threefold higher risk of recurrent ICH (RR, 3.20; 95% CI, 1.30-7.85). This elevated risk corresponds to a number needed to harm (NNH) of 22.
The study found no significant differences in the rates of fatal ischemic stroke, fatal ICH, major extracranial hemorrhage, myocardial infarction, or cardiovascular death based on OAC use.
Implications for clinical Practice
The researchers emphasized that these findings are crucial for informing shared decision-making between clinicians and patients.”This meta-analysis informs shared decision-making between clinicians and patients, demonstrating a net clinical benefit of oacs [oral anticoagulants] predominantly through a reduction in ischemic stroke/systemic thromboembolism, while being cognizant of an increased risk of recurrent ICH,” the authors stated.
They further noted that the magnitude of benefit and risk might vary depending on the specific subtype of ICH and the timing of OAC initiation. This suggests a need for further investigation through individual patient data meta-analyses to refine these insights.
Study Details and Limitations
this research was led by Kuan-Yu Chi, MD, and Pei-Lun Lee, MD, from Jacobi Medical Center, Albert Einstein College of Medicine in New york City, and Yu chang, MD, from the National Cheng Kung University in Tainan, Taiwan. The study was published online on July 21, 2025, in the Journal of the American College of Cardiology*.
The study acknowledged several limitations, including the lack of individual patient data, which precluded deeper analyses such as the timing of events. Additionally, the number of included trials and participants was insufficient to detect effects on less frequent outcomes.All included trials were open-label in design.
Disclosures
Several authors reported financial disclosures,including research funding and awards from various institutions such as the Johns Hopkins University Claude D. Pepper Older Americans Independence Center, the National Institute on Aging, the National Heart, Lung, and Blood Institute, and the National Institutes of Health. One author also reported serving as a consultant for Novo Nordisk,Merck,and HeartFlow,Inc.